Pain biotech Cara Therapeutics sets terms for $60 million IPO

Shutterstock photo

Cara Therapeutics, a clinical-stage biotech developing novel opioid pain medication, announced terms for its IPO on Friday. The Shelton, CT-based company plans to raise $60 million by offering 5.0 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Cara Therapeutics would command a market value of $262 million.

Cara Therapeutics, which was founded in 2004 and booked $11 million in grant and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol CARA. Cara Therapeutics initially filed confidentially on October 4, 2013. Stifel and Piper Jaffray are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Research Brokers before you trade

Want to trade FX?

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by